Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-stroke Spasticity of the Upper Limb
Latest Information Update: 07 Dec 2018
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Registrational; Therapeutic Use
- Acronyms PURE
- Sponsors Merz Pharmaceuticals GmbH
- 27 Nov 2018 Results of open label extension (OLEX) assessing efficacy and safety published in the Advances in Therapy.
- 28 Apr 2017 Pooled analysis results of two phase 3 clinical studies (NCT01392300 and NCT00432666) in upper-limb post-stroke spasticity assessing the duration of treatment effect for incobotulinumtoxinA treatment intervals, presented at the 69th Annual Meeting of the American Academy of Neurology.
- 16 Aug 2016 Results (n=572) of this and two other phase 3 trials published in the Drugs (2016).